(Q40333505)

English

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

scientific article published on 19 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

author name string

J D Wark

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

W Bensen

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

C Recknor

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

O Ryabitseva

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

J Chiodo

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

P Mesenbrink

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

T J de Villiers

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

19 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Osteoporosis International

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

503-512

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1563-8

21 January 2018

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1563-8

21 January 2018

Characterization of and risk factors for the acute-phase response after zoledronic acid

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1563-8

21 January 2018

Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1563-8

21 January 2018

Safety considerations with bisphosphonates for the treatment of osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1563-8

21 January 2018

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

https://api.crossref.org/works/10.1007%2FS00198-011-1563-8

21 January 2018

Identifiers

10.1007/S00198-011-1563-8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40333505&oldid=2203609948"